Keywords

abaloparatide, abemaciclib, acalabrutinib, avelumab, axicabtagene, benznidazole, brigatinib, cerliponase alfa, copanlisib dihydrochloride, deflazacort, delafloxacin meglumine, durvalumab, emicizumab-kxwh, enasidenib mesylate, etelcalcetide hydrochloride, latanoprostene bunod, letermovir, meropenem trihydrate, midostaurin, neratinib maleate, niraparib tosylate monohydrate, ribociclib succinate, secnidazole, telotristat ethyl, tisagenlecleucel, vestronidase alfa-vjbk

 

Authors

  1. Hussar, Daniel A. PhD

Abstract

Abstract: This article discusses eight drugs recently approved by the FDA, including their indications and contraindications, precautions, dosage, and nursing considerations. The article also includes summary charts on 14 recently approved antineoplastic drugs and four drugs approved for rare disorders.